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Hematologic malignancies represent the fourth most frequently diagnosed cancer in
economically developed countries. In hematologic malignancies normal hematopoiesis
is interrupted by uncontrolled growth of a genetically altered stem or progenitor cell
(HSPC) that maintains its ability of self-renewal. Cyclin-dependent kinases (CDKs) not
only regulate the mammalian cell cycle, but also influence other vital cellular processes,
such as stem cell renewal, differentiation, transcription, epigenetic regulation, apoptosis,
and DNA repair. Chromosomal translocations, amplification, overexpression and altered
CDK activities have been described in different types of human cancer, which have
made them attractive targets for pharmacological inhibition. Mouse models deficient
for one or more CDKs have significantly contributed to our current understanding
of the physiological functions of CDKs, as well as their roles in human cancer. The
present review focuses on selected cell cycle kinases with recent emerging key functions
in hematopoiesis and in hematopoietic malignancies, such as CDK6 and its role in
MLL-rearranged leukemia and acute lymphocytic leukemia, CDK1 and its regulator
WEE-1 in acute myeloid leukemia (AML), and cyclin C/CDK8/CDK19 complexes in T-cell
acute lymphocytic leukemia. The knowledge gained from gene knockout experiments
in mice of these kinases is also summarized. An overview of compounds targeting
these kinases, which are currently in clinical development in various solid tumors and
hematopoietic malignances, is presented. These include the CDK4/CDK6 inhibitors
(palbociclib, LEE011, LY2835219), pan-CDK inhibitors that target CDK1 (dinaciclib,
flavopiridol, AT7519, TG02, P276-00, terampeprocol and RGB 286638) as well as the
WEE-1 kinase inhibitor, MK-1775. The advantage of combination therapy of cell cycle
inhibitors with conventional chemotherapeutic agents used in the treatment of AML, such
as cytarabine, is discussed.
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Introduction
Hematologic malignancies account for around 9% of all cancers and represent the fourth
most frequently diagnosed cancer in both men and women in economically developed
regions of the world (Smith et al., 2011). Around 50% of the children with cancer, younger
than 15, have leukemia or lymphoma and acute myeloid leukemia (AML) is responsible
for approximately half of the leukemic deaths in children (Meshinchi and Arceci, 2007).
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Normal hematopoiesis is dependent upon tightly controlled
and inter-related mechanisms regulating cell proliferation and
differentiation. Hematopoiesis is initiated in the bone marrow
(BM) by multipotent hematopoietic stem cells (HSC). The HSC
population is relatively quiescent (Bradford et al., 1997; Cheshier
et al., 1999), but upon cell cycle entry it will give rise to dif-
ferentiating progenitor populations that undergo massive pro-
liferative expansion in order to replenish the blood system on a
daily basis but also in response to stress, such as injury or infec-
tion (Weissman, 2000). Quiescence is thought to prevent stem
cell exhaustion (Orford and Scadden, 2008) and to help protect
stem cells from acquiring mutations leading to their malignant
transformation (Park and Gerson, 2005; Wang and Dick, 2005;
Lobo et al., 2007). Therefore, the balance between proliferation
and quiescence in HSCs must be carefully regulated to ensure
homeostasis (Wilson et al., 2008). Cell cycle regulators play a
crucial role in controlling these processes and have been previ-
ously reviewed (Passegue et al., 2005; Pietras et al., 2011; Tesio
and Trumpp, 2011; Cabezas-Wallscheid et al., 2014). The current
review will focus on the impact of such cell cycle regulators on
hematological-derived cancers and their potential as therapeutic
targets.
Acute Myeloid Leukemia from Mutations to
Dysregulated Pathways Leading to
Aberrant Cell Proliferation
Approximately 300 genes have been reported to be altered in
hematologicmalignancies (Catalog of SomaticMutations in Can-
cer at the Wellcome Trust Sanger institute). In most hematologic
malignancies, normal hematopoiesis is interrupted by uncon-
trolled growth of a genetically altered stem or progenitor cell.
AML, which accounts for 75% of acute leukemia, is a complex
and heterogeneous disease (Appelbaum et al., 2007). In AML, a
HSC or progenitor cell will be transformed to a leukemia stem cell
(LSC) through accumulation of genomic alterations that enable
the LSC to maintain its ability of self-renewal but without normal
terminal differentiation (Renneville et al., 2008).
Several lines of evidence have led to a model that AML arises
from the cooperation between two classes of genetic alterations
(Gilliland et al., 2004) in which class I mutations confer a prolifer-
ation or survival advantage to blast cells. These typically include
genes encoding key proliferative tyrosine kinase receptors, such
as the FMS-like tyrosine kinase 3 (FLT3) and c-KIT, as well as
down-stream signaling regulators, such as the RAS oncogene and
PTPN11 (protein tyrosine standard phosphatase non-receptor
11) gene that encodes SHP-2. Other mutated genes in this cate-
gory include JAK2 and the IL-3 receptor family.Class II mutations
that impair myeloid differentiation typically include mutations
in the AML1 (CBFA2 or RUNX1), CEBPA, WT1 and PU.1 (Ren-
neville et al., 2008; Arceci and Aplenc, 2009; Pui et al., 2011; Schn-
erch et al., 2012). The interplay of dysregulated proliferative and
differentiation pathways in turn have important consequences
for the altered regulation of the cell cycle controllers, such as
cyclins, cyclin-dependent kinases (CDKs), checkpoint kinases,
and mitotic kinases.
Furthermore, mutations in genes regulating chromatin and/or
methylation states in hematopoietic progenitors are emerging as
critical events in AML and have prognostic importance. These
genes include the tet methylcytosine dioxygenase 2 (TET2),
mutated in 7–25% of AML, the isocitrate dehydrogenase 1 (IDH1,
IDH2), mutated in 15–30% of AML and the DNA methyl-
transferase 3A (DNMT3A), mutated in 15–25% of AML (Shih
et al., 2012; Conway O’brien et al., 2014; Greenblatt and Nimer,
2014).
Targeted cancer therapies are developed to interrupt a specific
component of the complex network of altered signaling path-
ways that ultimately results in uncontrolled cell proliferation.
However, there is a significant cross talk between these signaling
pathways and the same pathway is usually activated by multi-
ple receptors. Therefore, if the function of one protein located
upstream the signaling pathway is inhibited another protein will
most likely compensate the interrupted function. The outcome
will still be uncontrolled cell proliferation. However, most of
these pathways converge in a signal that activates the cell cycle,
which consists of a series of well-defined, unidirectional sequence
of events from G1 to M. Therefore, blocking one phase of the cell
cycle should theoretically interrupt the remaining phases and halt
proliferation.
The present review focuses on the alterations and therapeu-
tic targeting of selected downstream cell cycle kinases based on
their emerging key functions in hematopoiesis and in the devel-
opment and progression of hematopoietic malignancies. A brief
overview of CDKs and their multifaceted biological functions is
first presented followed by the rationale for their therapeutic tar-
geting. Although human tumors are more genetically complex
than mouse tumors, genetically engineered mouse models have
significantly contributed to our understanding of CDK functions
in normal development and remain indispensable for under-
standing the development and progression of human cancer, as
well as response to treatment. For each of the following cell cycle
kinases: CDK6, CDK1, WEE-1 and cyclin C/CDK8/CDK19 we
will present (1) an overview of the current knowledge of their
biological functions gained from knockout mouse models, (2) the
role of each protein in human cancer with emphasis on hemato-
logic malignancies, and (3) the pharmacological inhibitors cur-
rently in clinical development to target these kinases in hemato-
logic malignancies.
Cyclin-Dependent Kinases
In order for a cell to undergo successful division, it has to perform
four key tasks in a highly ordered fashion. First, there is a prepara-
tory synthetic phase (G1) that results in an increased cell size in
anticipation of DNA replication (S phase). Cells then proceed
through (G2-phase) to prepare to equally segregate duplicated
DNA (M phase) and finally divide into two equal daughter cells.
From G1 a cell can also exit the cell cycle and enter a state of qui-
escence (G0), undergo differentiation or re-enter the cell cycle to
proliferate in response to mitogenic signals.
The core molecular machinery controlling the mammalian
cell cycle consists of a family of serine/threonine protein kinases
called cyclin-dependent kinases (CDKs). These are catalytic
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subunits, which are activated in most cases by association
with cyclin regulatory subunits. The activity of CDK/cyclin
complexes is further regulated by CDK-inhibitors (CKIs),
phosphorylation and dephosphorylation, ubiquitin-mediated
degradation, transcriptional regulation, substrate recognition,
and subcellular localization (Aleem and Kaldis, 2006). The
family of CDKs/cyclins/CKIs contains more than 30 members
(Figure 1; Supplementary Table 1) and they are implicated in
essential cellular functions such as transcription, DNA damage
repair, epigenetic regulation, metabolism, proteolytic degrada-
tion, stem cell self renewal, neuronal functions, and spermato-
genesis (Lim and Kaldis, 2013).
CDKs with Direct Functions in Cell Cycle
Regulation
The classical CDKs that directly regulate the mammalian cell
cycle in complexes with cyclin subunits include CDK3, CDK4,
CDK6, CDK2, and CDK1. CDK3 promotes cell cycle entry from
quiescence in association with cyclin C (Ren and Rollins, 2004).
CDK8 has also been suggested to play a role in cell cycle entry
from G0 and in the G1/S transition (Szilagyi and Gustafsson,
2013). In its simplest model, the mammalian cell cycle pro-
ceeds as follows: In early G1, CDK4/CDK6 in complex with
FIGURE 1 | Cyclin-dependent kinases (CDKs) and their cyclin
regulatory subunits. CDK-cyclin complexes with direct functions in
regulating the cell cycle. CDK3/cyclin C drives cell cycle entry from G0.
CDK4/6/cyclin D complexes initiate phosphorylation of the retinoblastoma
protein (pRb) and they sequester p21Cip1 and p27kip1 (not shown), which are
both inhibitors of CDK2, thus promoting the activation of CDK2/cyclin E
complex. In late G1, CDK2/cyclin E complex completes phosphorylation and
inactivation of pRb, which releases the E2F transcription factors and G1/S
transition takes place. DNA replication takes place in S phase. CDK2/cyclin A
complex regulates progression through S phase and CDK1/cyclin A complex
through G2 phase in preparation for mitosis (M). Mitosis is initiated by
CDK1/cyclin B complex. The activity of CDK1/cyclin B is tightly regulated by
activating phosphorylation by the CDK-activating kinase CAK (a heterodimer
of cyclin H-CDK7-MAT1) and inhibitory phosphorylations by Wee1 and Myt1
on Tyr15 and Thr14 (not shown). The specific CDK4/CDK6 pharmacological
inhibitors described in this study are shown.
cyclin D receive mitogenic signals that result in activation of
cell cycle entry (Figure 1). Key signaling events include initia-
tion of retinoblastoma protein (pRb) phosphorylation and the
sequestration of p21Cip1 and p27kip1, which are both inhibitors
of CDK2, thus promoting the activation of CDK2/ cyclin E com-
plex (Sherr and Roberts, 1999). In late G1, CDK2 in complex with
cyclin E completes the phosphorylation and hence inactivation of
pRb, which in turn releases the E2F transcription factors (Kaldis
and Aleem, 2005). E2F promotes transcription of cyclin E that is
necessary for the G1/S transition.
Progression through S phase is mediated by CDK2/cyclin
A complex. Mitosis is then initiated by CDK1/cyclin B com-
plexes. CDK1/cyclin A complexes contribute to the preparation
for mitosis in G2 phase (Nigg, 1995; Edgar and Lehner, 1996).
The activity of CDK1/cyclin B is tightly regulated by activating
phosphorylation by the CDK-activating kinase (CAK) (a het-
erodimer of cyclin H and CDK7) and inhibitory phosphoryla-
tions by WEE-1 and Myt1 on Tyr15 and Thr14. Mitosis starts
after WEE-1 is degraded and CDC25C phosphatase releases the
inhibitory phosphorylation on CDK1/cyclin B.
CDKs with Transcriptional and Other
Functions
In addition to their direct role in the mitotic cell cycle regula-
tion, some classical CDK/cyclin complexes have essential func-
tions in meiosis, such as CDK2 (Berthet et al., 2003; Ortega
et al., 2003), in transcription and/or DNA repair (e.g., CDK1,
CDK2, CDK6) (Satyanarayana and Kaldis, 2009; Neganova et al.,
2011; Wohlbold et al., 2012; Kollmann et al., 2013; Lim and
Kaldis, 2013; Scheicher et al., 2015). Other CDKs (referred to
in Supplementary Table 1 as non-classical CDKs) act by activat-
ing the classical CDKs, such as CDK7/cyclin H (CAK) and the
related CDK20, also known as cell cycle related kinase (CCRK)
(Wohlbold et al., 2006). Some CDKs function mainly in influ-
encing transcription by phosphorylating the carboxy-terminal
domain (CTD) of ribonucleic acid (RNA) polymerase II (RNA
pol II) (Bose et al., 2013; Lim and Kaldis, 2013) (Supplemen-
tary Table 1). This phosphorylation also serves as a platform for
RNA processing and chromatin regulation (Hirose and Ohkuma,
2007).
CDKs that have important transcriptional roles include
CDK7/cyclin H/MAT1 complex, a component of the basal tran-
scription factor, TFIIH and facilitates transcriptional initiation
(Shiekhattar et al., 1995). CDK8/cyclin C, in addition to its role
in transcription (Gonzalez et al., 2014), is also involved in the
Wnt/β-catenin pathway (Firestein et al., 2008) and in inhibition
of lipogenesis (Zhao et al., 2012). Cyclin C can recruit CDK8 or
CDK19 to the CDK8 module of the Mediator complex, which
can function as a positive or negative regulator of transcription
by RNA pol II (Li et al., 2014; Trakala and Malumbres, 2014).
CDK3/cyclin C also plays a role in NHEJ-mediated DNA damage
repair (Tomashevski et al., 2010). While CDK9 in complex with
cyclin T forms the phospho-transcription elongation factor b
(p-TEFb) and promotes transcriptional elongation (Shapiro,
2006), CDK9 also functions in the DNA damage response when
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complexed with cyclin K (Yu et al., 2010). CDK10/cyclin M
phosphorylates the Ets2 transcription factor and positively con-
trols its degradation by the proteasome. Ets2 plays key roles in
cancer and development (Guen et al., 2013). CDK11/cyclin L
controls the assembly of the RNA pol II mediator complex (Dro-
gat et al., 2012). CDK12 and CDK13 in complex with cyclin K
control RNA pol II transcription (Bartkowiak et al., 2010; Blazek
et al., 2011; Cheng et al., 2012), and CDK12/cyclin K controls
DNA damage response (Blazek et al., 2011). These functions are
summarized in Supplementary Table 1.
CDKs with additional functions include CDK5, which plays
an important role in controlling neural development and post-
synaptic signal integration (Kim and Ryan, 2010), and influ-
ences epigenetic regulation through its interaction with Dnmt1
(Lavoie and St-Pierre, 2011). CDK5 also regulates degranulation
in human eosinophils (Odemuyiwa et al., 2015). CDK5 plays a
role in diabetes; it phosphorylates the peroxisome proliferator-
activated receptor γ (PPARγ) at Ser 273, thus stimulating dia-
betogenic gene expression in adipose tissue (Choi et al., 2010).
CDK5 also suppresses ERK2 through direct phosphorylation
(Banks et al., 2015). CDK14/cyclin Y is involved in the Wnt/β-
catenin pathway (Davidson et al., 2009). CDK15 was reported to
attenuate Tumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL)-induced apoptosis by phosphorylation of survivin
(Park et al., 2014). CDK16 in complex with cyclin Y regulates
spermatogenesis (Mikolcevic et al., 2012). CDK17 and CDK18
are not well-characterized but a recent report demonstrated that
CDK18 is phosphorylated and activated by cyclin A2 and cAMP-
dependent protein kinase (PKA) and its knockdown induced
polymerized actin accumulation in peripheral areas and cofilin
phosphorylation (Matsuda et al., 2014). Furthermore, CDK18 is
highly expressed in diabetic human pancreatic islets (Taneera
et al., 2013). CDK20 plays a role in ciliogenesis (Ko et al., 2010;
Phirke et al., 2011; Yang et al., 2013a)(Supplementary Table 1).
Because of the transcriptional role played by multiple CDKs,
pan CDK inhibitors, such as flavopiridol, not only arrest the cell
cycle but can interfere with cellular transcription and reduce the
expression of short-lived mRNAs and proteins, which include
cell cycle regulators and survival factors, such as Mcl-1, thus
promoting cell death (Bruyere and Meijer, 2013).
Rationale for Therapeutically Targeting
CDKs in Cancer
The activity of CDK/cyclin complexes is frequently perturbed
in human cancer (Lapenna and Giordano, 2009; Malumbres
and Barbacid, 2009). Some CDKs can be considered oncogenic,
e.g., CDK4 in familial melanoma (Zhao et al., 2012), CDK6 in
MLL-rearranged leukemia (Placke et al., 2014), and CDK8 in
colon cancer (Firestein et al., 2008). Alteration of CDK-encoding
genes or their partner cyclins can lead to their overexpression,
amplification and translocation, e.g., cyclin D1 alterations are
observed in chronic lymphocytic leukemia (CLL), B-cell acute
lymphocytic leukemia (B-ALL), mantle cell lymphoma (MCL),
and multiple myeloma (MM). Cyclin D2 translocation and over-
expression are described in non-Hodgkins’ lymphoma (NHL),
CLL, B cell lymphocytic leukemia (BLL) and lymphoplasmacytic
lymphomas (LPL). Cyclin D3 translocations are observed in MM
and in diffuse large B cell lymphomas (DLBCL) (Supplementary
Table 2). In addition to genetic changes, CDK hyperactivation
may result from overexpression of positive regulators such as
cyclins or the inactivation of their inhibitors, from alternative
splicing and expression of truncated cyclin variants or abnor-
mal localization (Peyressatre et al., 2015). For example, CDK2 has
not been found mutated in human cancer (Malumbres and Bar-
bacid, 2009). However, its inhibition significantly reduced tumor
growth of trastuzumab-resistant xenografts from patients with
Her+/amplified cyclin E breast cancer (Scaltriti et al., 2011). Sim-
ilarly, alterations in the expression and activity of CDK1 have
been observed in breast (Kim et al., 2008), gliomas (Chen et al.,
2008), lung (Zhang et al., 2011), and colon cancer (Zeestraten
et al., 2012). Although the total CDK1 level is high in aggres-
sive NSCLC, its subcellular localization is an important factor
because loss of cytoplasmic CDK1 is associated with a poor prog-
nosis (Zhang et al., 2011). Aberrations in transcriptional CDKs
with direct modulation of target genes have also been described
in human cancer such as CDK8, CDK9/cyclin T1, CDK10, and
CDK11 (Peyressatre et al., 2015).
The pharmacological inhibition of CDKs typically results in
cell cycle arrest, apoptosis, and transcriptional repression. Cur-
rently, inhibitors targeting the transcriptional CDKs such as
CDK7 and CDK9 are in preclinical development (Kwiatkowski
et al., 2014; Walsby et al., 2014). Interestingly, in mouse mod-
els the kinase activities of some cyclin/CDK complexes, such as
CDK4 and CDK2, appear dispensable for normal mouse devel-
opment, but are required for mammary tumor development (Yu
et al., 2006; Ray et al., 2011). This provides a possibly selec-
tive targeting of tumor cells with potential, relative sparing of
normal cells.
Targeting CDKs in Hematologic
Malignancies
CDK4/CDK6-Cyclin D
CDK4 and CDK6 both bind the D-type cyclins and their kinase
activities are inhibited by the INK4 (Inhibitors of CDK4) fam-
ily of CDK inhibitors, which includes p16INK4a. p16INK4a is the
most frequently deleted locus in human cancer (Beroukhim et al.,
2010); its loss of function can result in a constitutively active
CDK4/6, thus driving uncontrolled proliferation. Pharmacolog-
ical inhibitors of CDK4/6 have been developed and are currently
being tested in clinical trials (Supplementary Table 3).
Mouse Models Reveal Unique Roles for CDK6 in
Hematopoiesis
CDK4 and CDK6 are highly homologous enzymes with basically
indistinguishable biochemical properties and play a redundant
role during G1/S transition. However, they are required by dif-
ferent tissues during mouse development and their deregulation
is associated with different types of human cancer. While CDK4
is required by the pancreatic beta cells and pituitary lactotrophs
in mice (Rane et al., 1999; Tsutsui et al., 1999; Moons et al., 2002;
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Martin et al., 2003; Jirawatnotai et al., 2004), CDK6 has a unique
role in hematopoiesis (Malumbres et al., 2004). CDK6 is pre-
dominantly expressed in hematopoietic cell types (Della Ragione
et al., 1997; Chilosi et al., 1998) and loss of CDK6 in mice causes
thymic atrophy and reduction in red blood cells, granulocytes,
macrophages, neutrophils and platelets, as well as delayed G1
progression in lymphocytes of Cdk6−/− mice, (Malumbres et al.,
2004). Moreover, Notch-dependent initiation of T-cell commit-
ment by BM progenitors requires CDK6 (Hu et al., 2009). CDK6
is also a key downstream target in the AKT pathway andCdk6−/−
mice are resistant to AKT-driven lymphomagenesis (Hu et al.,
2009).
CDK6 in Human ALL, T-LBL, and Lymphoma
CDK6 is highly expressed in human T-cell lymphoblastic lym-
phoma/leukemia (T-LBL/ALL) (Chilosi et al., 1998; Lien et al.,
2000; Schwartz et al., 2006; Nagel et al., 2008). CDK6 is also a tar-
get of the tumor suppressor microRNA hsa-mir-124a, which is
frequently hypermethylated and downregulated in ALL (Agirre
et al., 2009). Epigenetic downregulation of mir-124a in vitro and
in vivo leads to overexpression of CDK6 and increased prolifera-
tion of ALL cells that is in turn decreased by the CDK6 inhibitor
palbociclib (PD0332991) (Agirre et al., 2009). In this study,
patients with ALL with methylation of hsa-miR-124a showed
a significant up-regulation of CDK6 expression compared with
non-methylated patients. Moreover, patients in the methylated
group had a significantly higher relapse and mortality rates as
well (Agirre et al., 2009). Hypermethylation of hsa-miR-124a was
also found to be an independent prognostic factor for disease-
free survival (DFS) and overall survival (OS) in patients with
ALL. Based on this, targeting CDK6 was suggested as a potential
therapeutic strategy for patients with ALL (Agirre et al., 2009).
Chromosomal translocations of CDK6 in patients suffering
from B-lymphoid cancers have been documented as well (Brito-
Babapulle et al., 2002). Although CDK4/CDK6 pharmacological
inhibitors were developed to target their kinase activity as the
cause for deregulated proliferation in cancer, additional impor-
tant cancer-relevant CDK6 kinase-independent functions have
been recently discovered in B-cell receptor (BCR)-ABL trans-
formed B-cell leukemia/lymphoma cells (Kollmann et al., 2013).
For instance, CDK6 overexpression has been reported to have an
anti-proliferative effect in vivo resulting in the delay of tumor
formation. The seemingly contradictory result may be due to
the ability of CDK6 to induce the expression of its inhibitor,
the tumor suppressor p16INK4a, which then arrests the cell cycle.
However, when p16INK4a is inactivated by promoter methylation
in a mouse model of T-cell lymphoma, CDK6 acts as an onco-
gene, as expected. Therefore, induction of p16INK4a by CDK6
protects cells from high CDK6 activity through a negative feed-
back loop (Otto and Sicinski, 2013). In transformed lymphoid
cells, the relative amounts of the two proteins define the rate
at which tumor progression occurs. This may also reflect the
situation in human lymphoid malignancies, where CDK6 and
p16INK4a are expressed in an inverse manner (Kollmann and
Sexl, 2013). In addition to the induction of p16INK4a, CDK6
also induces transcription of vascular endothelial growth factor
A (VEGFA), a known angiogenic factor and tumor promoter,
thereby linking two hallmark cancer features (Kollmann and Sexl,
2013; Otto and Sicinski, 2013). CDK6 binds the promoters of
p16INK4a and VEGF-A through interaction with the transcription
factors STAT-3 and c-Jun (Kollmann et al., 2013). Thus, CDK4/6
inhibitors may have a dual effect in the types of malignancies
with p16INK4a deletion, as they will target both proliferation and
angiogenesis.
CDK6 is a Driver and Therapeutic Target in
MLL-Rearranged AML, in Infant ALL and in
FLT3-ITD Driven AML
The mixed lineage leukemia (MLL) gene, located on chromo-
some 11q23, has important roles in epigenetic patterning in
leukemia (Jin et al., 2010). Chromosomal rearrangements involv-
ing the MLL gene are found in 5–10% of pediatric and adult
AML (Antony-Debre and Steidl, 2014), and in 80% or greater in
cases of infant ALL (Van Der Linden et al., 2014); these translo-
cations are usually associated with a poor prognosis. t(11q23)
results in fusion of the MLL gene to a broad spectrum of part-
ner genes (Meyer et al., 2013). A key functional feature of (MLL)
rearrangements is their ability to confer leukemia-initiating activ-
ity to HSPC (Krivtsov et al., 2008). Recently, CDK6 was found
to be a direct target of MLL-fusion proteins in MLL-AF9-driven
AML (Placke et al., 2014) and of infant MLL-AF4-driven ALL
(VanDer Linden et al., 2014), resulting in the transcriptional acti-
vation of CDK6. This was shown in cell lines, a murine model
of MLL-AF9-driven AML, and in infant ALL patient samples. A
likely key mechanism by which CDK6 drives MLL-AF9-driven
AML is through inhibition of myeloid differentiation (Placke
et al., 2014). An earlier report also identified CDK6 as a tar-
get of microRNA-29a, which regulates myeloid differentiation in
HSPCs and in AML cell lines (Wang et al., 2013). These stud-
ies showed that the catalytic activity of CDK6 is required for
this function because expression of a mutant form of CDK6
with disrupted kinase function is unable to block the differ-
entiation induced by shRNA-mediated depletion of CDK6 in
MLL-rearranged AML cells (Placke et al., 2014).
About 25% of cases of AML express a constitutively active
FLT3 internal tandem duplication (FLT3-ITD), an activating
mutant form of the receptor tyrosine kinase FLT3 (Rombouts
et al., 2000; Small, 2006). Inhibition of FLT3-ITD in AML
leads to down regulation of cyclin D2 and D3, both activa-
tors of CDK6 (Wang et al., 2007), which suggests that CDK6
may be an additional candidate for therapeutic targeting in
FLT3-ITD-driven AML.
Mouse Models of the D-Type Cyclins Reveal
Essential Roles in Hematopoiesis
The D-type cyclins, especially D2 and D3, which bind and
activate CDK4/CDK6, play unique roles in hematopoiesis, and
hematologicmalignancies.Mice lacking cyclin D2 show impaired
proliferation of B-lymphocytes (Kushner et al., 2005) and cyclin
D3−/− mice display hypoplastic thymuses and are resistant to
Notch-driven leukemia (Sicinska et al., 2003). Moreover, ablation
of cyclin D3 in mice bearing Notch1-driven T-cell acute lym-
phoblastic leukemia (T-ALL) triggers tumor cell apoptosis. Such
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selective killing of leukemic cells can also be achieved by inhibit-
ing cyclin D-associated kinase activity in mouse and human T-
ALL models (Choi et al., 2012). Acute ablation of the 3 D-type
cyclins in adult mouse BM revealed that adult HSCs are depen-
dent on D-type cyclins for survival, and their loss results in mas-
sive apoptosis of all hematopoietic cell types due to upregulation
of the expression of the death receptor Fas and its ligand FasL
(Choi et al., 2014).
Genomic Alterations of the D-Type Cyclins in
Hematologic Malignancies
Chromosomal translocation involving cyclin D1 is a common
genetic event in the pathogenesis of B-cell lymphomas, espe-
cially MCL (Supplementary Table 2). MCL is characterized by
the t(11;14)(q13;q32) translocation that juxtaposes the cyclin D1
gene (CCND1) to the immunoglobulin (Ig) heavy chain gene
(Bertoni et al., 2006), and results in constitutive overexpression
of cyclin D1 under the control of an active Ig locus (Baker and
Reddy, 2012). Single nucleotide polymorphisms are also thought
to contribute to increased levels of cyclin D1 via production of
an alternatively spliced isoform (Baker and Reddy, 2012). The
G/A870 polymorphism is thought to hinder normal splicing at
the exon 4/5 boundary resulting in the expression of a truncated
cyclin D1 protein (Betticher et al., 1995), cyclin D1b, that forms
an active complex with CDK4, (Lu et al., 2003; Solomon et al.,
2003) but it lacks the residue necessary for nuclear export and
subsequent cytoplasmic degradation (Diehl et al., 1997), thereby
stabilizing cyclin D1 protein and increasing its oncogenic poten-
tial (Alt et al., 2000). The CCND1 A/A variant has been linked to
increased susceptibility (Hou et al., 2005) and a lower probability
of event-free survival in children with ALL compared to carriers
of the G variant (Costea et al., 2003).
Cyclin D2 protein frequently shows high levels of expression
in B cell malignancies, such as BLL, LPL (Delmer et al., 1995)
and in CLL (Motokura and Arnold, 1993). Cyclin D2 is essential
for BCR-dependent proliferation of B cells (Mohamedali et al.,
2003) and for BCR/ABL-dependent transformation of BM cells
(Jena et al., 2002). Patients with chronic myeloid leukemia (CML)
carry the BCR/ABL fusion protein (De Klein et al., 1982; Shtivel-
man et al., 1985). Therefore, modulation of its downstream tar-
get cyclin D2-associated activity may be important in CML. The
t(6;14)(p21.1;q32.3) translocation that juxtaposes the CCND3
and IGH loci resulting in high-level expression of CCND3 has
been reported in MM (Bergsagel and Kuehl, 2001) and in sev-
eral subtypes of mature B-cell malignancies including DLBCL
(Sonoki et al., 2001).
While there are no inhibitors that directly target cyclin D,
alternative therapeutic strategies targeting CDK4/CDK6 could
be potentially useful in hematologic malignancies with altered
D-type cyclins.
CDK4/CDK6 Inhibitors
Palbociclib
Palbociclib (PD0332991, Pfizer) is an orally administered small
molecule inhibitor of CDK4/6 (Fry et al., 2004) undergoing
active clinical trial testing (Supplementary Table 3). As pRb is
a substrate of CDK4/6-cyclin D, palbociclib targets Rb+ tumor
cells in vitro, inducing G1 arrest, with concomitant elimination
of phospho-Rb and inhibition of E2F-dependent transcription
(Bose et al., 2013).
Because of the critical role played by CDK6 in MLL-
rearranged AML and ALL, as well as in FLT3-ITD driven AML,
CDK6 may be an effective therapeutic target in these leukemias.
In AML cell lines bearing the FLT3-ITD mutation, PD0332991
as single-agent induces sustained cell cycle arrest and prolonged
survival in an in vivo model of FLT3-ITD AML (Wang et al.,
2007). It also causes an initial cell-cycle arrest in well-established
FLT3 wild-type (wt) AML cell lines, but this is overcome by
down-regulation of p27Kip1 and reactivation of CDK2. This
acquired resistance is not observed in FLT3-ITD and a FLT3 wt
samples from patients with primary AML (Wang et al., 2007).
This study suggests the activation of CDK2 as a potential mech-
anism of resistance to PD0332991. Therefore, it might be worth-
while to test combined inhibition of CDK4/CDK6 and CDK2
in such cases, while closely monitoring toxicity. Flavopiridol
and AT7519 (discussed below) are drugs that target six CDKs
including CDK2/4/6 (Bose et al., 2013). Although in vitro stud-
ies consider CDK2 to be a major player in proliferation and
apoptosis in hematopoietic cells, it is not required for prolifer-
ation and differentiation of hematopoiesis in vivo (Berthet et al.,
2007).
In MLL-rearranged leukemia, PD0332991 strongly inhibits
colony formation in methylcellulose of MLL-AF9 positive AML
cell lines and of mononuclear cells from patient derived AML
samples (Placke et al., 2014). Furthermore, inhibition of CDK4/6
kinase activity using PD0332991 leads to inhibition of cell cycle
progression and accumulation in the Go/G1cell cycle phase in
T-ALL primary samples, triggers apoptosis, and blocks pro-
gression of leukemia in a mouse model of T-ALL (Sawai
et al., 2012). Preclinical testing has also demonstrated effi-
cacy of PD0332991 in MM in vitro and in vivo and in MCL
(Baughn et al., 2006; Marzec et al., 2006). It potently induces
G1 arrest, but not apoptosis, in primary BM myeloma cells
ex vivo. In addition, PD0332991 markedly enhances the killing
of myeloma cells by dexamethasone (Baughn et al., 2006). In
the 5T33MM myeloma mouse model, PD0332991 treatment
leads to tumor suppression and a significant improvement
in survival. Induction of G1 arrest by PD0332991 sensitizes
5T33MM tumor cells to killing by bortezomib (Menu et al.,
2008).
The Food and Drug Administration designated palbociclib
a breakthrough therapy in April 2013 (Brower, 2014). Cur-
rently, there are 36 clinical studies that are either completed
or ongoing involving PD0332991 as single agent or in com-
bination with other drugs for the treatment of various types
of cancer (clinicaltrials.gov, accessed 11/2014). Seven studies
involve hematologic malignancies (Supplementary Table 3) and
29 studies are for advanced solid malignancies. Phase I trials
are being done for patients with MM, MCL, acute leukemia
(AL), NHL and myelodysplasia (MDS). Two completed phase I
studies have established dosing regimens of 200mg daily for 2
weeks followed by 7 days off treatment (21-day cycles; Sched-
ule 2/1) (Schwartz et al., 2011), or 125mg daily for 3 weeks
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of 4 (Flaherty et al., 2012). In each case, neutropenia was the
dose-limiting toxicity (DLT). This toxicity profile is probably a
result of transient growth arrest in hematopoietic precursor cells
(Roberts et al., 2012). Other side effects associated with conven-
tional cytotoxic drugs, such as gastrointestinal toxicity, alope-
cia, or mucositis, fever or infection, were rare (Dickson, 2014).
PD0332991 has also shown promising activity in 17 patients with
relapsed MCL. Five patients achieved progression-free survival
(PFS) of greater than a year, with 1 complete (CR) and 2 par-
tial responses (PRs) (18% objective response rate) (Leonard et al.,
2012).
LEE011
LEE011 (Novartis) is an orally bioavailable small molecule that
inhibits CDK4/6 at nanomolar concentrations (Gelbert et al.,
2011; Kim et al., 2013). LEE011 demonstrated antitumor activity
in several models. There are currently 16 active clinical trials with
LEE011 as single agent or in combination with other drugs. Most
of the trials are for solid tumors, including melanoma with BRAF
or NRAS mutations, and breast cancer, neuroblastoma, malig-
nant rhabdoid tumors (clinicaltrials.gov, accessed 11/2014). Two
trials are in lymphomas (Supplementary Table 3). Results from
a phase I study in patients with advanced solid tumors or lym-
phomas recommended doses of 600mg daily (continuous) and
900mg daily for 3 weeks of 4 for subsequent Phase II trial testing.
As with palbociclib, neutropenia was the major toxicity (Infante
et al., 2013; Dickson, 2014).
Abemaciclib
Abemaciclib formerly LY2835219 (Eli Lilly), like palbociclib and
LEE011 is a small molecule selectively targeting CDK4/CDK6
and is orally available. Preclinical data for abemaciclib show anti-
tumor activity in a number of models, and the drug has also
been shown to cross the blood–brain barrier (Sanchez-Martinez
et al., 2011). There are 10 ongoing clinical trials using abemaci-
clib as a single agent or in combination for the treatment of
solid tumors, such as breast and lung cancer; as well as for
lymphoma and MCL (Supplementary Table 3; clinicaltrials.gov,
accessed 11/2014). There are 3 Phase III trials (Stage IV NSCLC
with a detectable KRAS mutation, and two trials for breast can-
cer). Themaximum tolerated dose (MTD) as recommended from
a Phase I study of abemaciclib in patients with advanced cancer
is 200mg twice daily (Shapiro et al., 2013). The most common
adverse effects were diarrhea, fatigue, and neutropenia.
In general, cancers with p16 loss may also be sensitive to
CDK4/CDK6 inhibition, with preclinical data supporting this
in melanoma and lung cancer among others (Sheppard and
Mcarthur, 2013) (Dickson, 2014). In contrast, cancers that lack
Rb function may be resistant to CDK4/CDK6 inhibition because
the antitumor effect of CDK4/CDK6 inhibition is partly due
to downstream Rb phosphorylation. This category of tumors
includes those with Rb loss at the gene level (such as Rb) and
those with functional inactivation of Rb protein, such as squa-
mous cell carcinomas of the oropharynx, cervix, and genital tract
in which the E7 oncogene of HPV16 inactivates Rb (Wiest et al.,
2002; Dickson, 2014).
CDK1
CDK1 Functions
CDK1 drives the cell cycle through G2 andM phases in associ-
ation with cyclin A and cyclin B, respectively. The phosphoryla-
tion of CDK1 on Thr14 (by Myt1 kinase) and Tyr15 (by WEE-1
kinase) (Mcgowan and Russell, 1995) inhibits its activity during
the G2 phase of the cell cycle, while its dephosphorylation on
the same sites by CDC25C results in its activation during early
mitosis (Boutros et al., 2007). Both CDK1 and WEE-1 inhibitors
are currently being used in clinical trials for the treatment of
hematologic malignancies (below).
Using genetically engineered mouse models it has been
demonstrated that CDK1 could drive all phases of the mam-
malian cell cycle in the absence of CDK2, CDK4, and CDK6
with subsequent phosphorylation of pRB (Santamaria et al.,
2007) by binding additionally to cyclin D and E and to the
inhibitors p27kip1 and p21Cip1/Waf1 (Aleem et al., 2005; Martin
et al., 2005; Santamaria et al., 2007; Satyanarayana et al., 2008).
Liver-specific deletion of CDK1 results in DNA re-replication
because of an increase in CDK2/cyclin A2 activity. Moreover, loss
of CDK1 in the mouse liver confers resistance against tumori-
genesis induced by activated Ras and silencing of p53 (Diril
et al., 2012). Furthermore, CDK1 plays a role in Myc-induced
transformation (Goga et al., 2007). Cells transformed by Myc
undergo apoptosis through down-regulation of the CDK1 target
survivin upon treatment with small-molecule CDK1 inhibitors.
CDK1 inhibitors also decrease tumor growth and prolong sur-
vival in mouse models of Myc-dependent lymphoma and hep-
atoblastoma (Goga et al., 2007). Similarly, targeting CDK1, but
not CDK4/6 or CDK2, is selectively lethal to MYC-dependent
human breast cancer cells (Kang et al., 2014). Thus, because there
are currently no compounds directly targeting Myc, CDK1 inhi-
bition may be an important therapeutic approach for human
malignancies that overexpress MYC.
CDK1 regulates vital cellular processes in addition to cell cycle
(Supplementary Table 2) (Lim andKaldis, 2013). CDK1 functions
in FoxM1 and FoxK2 transcription (Chen et al., 2009; Marais
et al., 2010), in homologos recombination-mediated DNA dam-
age repair (Huertas et al., 2008; Chen et al., 2011), in embryonic
stem cells (ESC) self-renewal through interaction with Oct4 (Li
et al., 2012), and in neural stem cell (NSC) self-renewal through
inhibition of Ngn2 (Ali et al., 2011). Furthermore, CDK1 plays
a role in epigenetic gene silencing and in mesenchymal stem
cell (MSC) differentiation. CDK1 and CDK2 phosphorylate the
enhancer of zeste homolog 2 (EZH2), a Polycomb group (PcG)
protein, at Thr 350 (Chen et al., 2010). EZH2 is a histone lysine
methyltransferase that catalyzes the addition of methyl groups to
histoneH3 at Lys 27 (H3K27) in target gene promoters, leading to
epigenetic silencing (Wei et al., 2011). EZH2 is the catalytic sub-
unit of Polycomb repressive complex 2 (PRC2), which includes
SUZ12 (suppressor of zeste 12) and EED (embryonic ectoderm
development) (Mrozek et al., 2001; Tenen, 2003). It enhances
cancer-cell invasiveness and regulates stem cell differentiation
(Wei et al., 2011). Phosphorylation of EZH2 by CDK1 and CDK2
at Thr350 is important for recruitment of EZH2 and mainte-
nance of H3K27me3 levels at EZH2-target loci, thus resulting in
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epigenetic silencing (Chen et al., 2010). Activation of CDK1 also
promotes MSC differentiation into osteoblasts through phos-
phorylation of EZH2 at Thr 487. This phosphorylation disrupts
EZH2 binding with the other PRC2 components SUZ12 and
EED, and inhibits EZH2 methyltransferase activity, resulting in
inhibition of cancer-cell invasion as well (Wei et al., 2011).
CDK1 in Hematologic Malignancies
It has been reported that CDK1 plays an important role in AML
(Biggs et al., 2006; Zhang et al., 2008; Radomska et al., 2012;
Hedblom et al., 2013) and in chronic myelomonocytic leukemia
(CMML) (Xu et al., 2014).
In AML, CDK1 expression in BM from newly diagnosed
patients was significantly lower than in BM from the same
patients at AML relapse (Hedblom et al., 2013). However, there
were no significant differences in CDK1 expression between BM
of patients at diagnosis and that at remission. This suggests that
CDK1 expression is associated with disease progression (Hed-
blom et al., 2013). Patients whose AML has higher levels of
nuclear CDK1 tends to have poorer clinical outcome compared
with those with lower levels (Hedblom et al., 2013). CDK1 is
also required to modulate the response to all-trans retinoic acid
(ATRA) through RARγ. For example, RARγ interaction with
ATRA regulates protein levels of CDK1 and its subcellular local-
ization; in turn, CDK1 modulates the levels of p27kip1 and AKT
phosphorylation in response to ATRA treatment. Therefore,
CDK1 modulation may represent a novel therapeutic approach
to overcome ATRA resistance (Hedblom et al., 2013).
RUNX1 (also called AML1), a target of CDK1, plays an essen-
tial role in normal hematopoiesis (Link et al., 2010). It regu-
lates lineage-specific genes and it directly stimulates G1 to S
cell cycle progression (Redondo et al., 1992; Nuchprayoon et al.,
1994; Zhang et al., 1994; Elagib et al., 2003). In agreement, adult
Runx1 conditional knockout mice show expansion of myeloid
cells, T-cell developmental abnormalities and thrombocytopenia
(Growney et al., 2005). Inactivating RUNX1mutations have been
described in myeloid neoplasms including MDS and cytogenet-
ically normal AML, thus RUNX1 can be considered a tumor
suppressor in these malignancies (Harada and Harada, 2011;
Schnittger et al., 2011). However, a certain level of RUNX1 activ-
ity was required for the growth and survival of AML1-ETO
and MLL-AF9 AML cells and combined loss of Runx1/Cbfb
inhibited leukemia development induced by MLL-AF9 (Goyama
et al., 2013). MLL binds to RUNX1 abrogating its proteasome-
dependent degradation (Huang et al., 2011). CDK2 and CDK1
phosphorylate RUNX1 on Ser276 and Ser303. These phospho-
rylations lead to its degradation during G2/M by Cdc20-APC
(Biggs et al., 2006). However, phosphorylation of RUNX1 at S48
and S424 by CDK1/cyclin B or CDK6/cyclin D3 modify RUNX1
to strengthen its ability to activate transcription and to stim-
ulate hematopoietic cell proliferation (Zhang et al., 2008). In
this context CDK1 inhibition may provide a therapeutic ben-
efit in MLL-rearranged leukemia through its ability to block
RUNX1. However, due to the dual role played by CDK1 in
regulating RUNX1 caution should be exercised when targeting
CDK1, as tissue-specific responses to CDK1 modulation may be
counter-therapeutic.
Mutations in FLT3 contribute to the development of AML as
they cause self-phosphorylation and ligand-independent activa-
tion of the FLT3 receptor and downstream signaling pathways
such as STAT3, STAT5, ERK1/2, and AKT (Hayakawa et al., 2000;
Mizuki et al., 2000, 2003; Tse et al., 2000; Spiekermann et al.,
2003). One of the targets of the ERK1/2 kinase is C/EBPα, a tran-
scription factor playing a critical role in granulocytic differenti-
ation (Ross et al., 2004). C/EBPα is often inactivated in various
subtypes of leukemia by multiple mechanisms, including phos-
phorylation of serine 21 that inhibits its function and results in
a differentiation block in FLT3-ITD leukemic blasts (Ross et al.,
2004; Radomska et al., 2006). CDK1 is an FLT3-ITD-activated
kinase, and is responsible for C/EBPα phosphorylation on ser-
ine 21 and for the blocking of its function (Radomska et al.,
2012). Hence pharmacologic inhibitors of CDK1 may be useful
for testing in FLT3-ITD driven leukemia.
Mutations of EZH2, TET2, IDH1/2, and DNMT3A involved
in epigenetic regulation are frequently observed in adult AML,
MDS, and myeloproliferative disease (MPD). Some of these gene
mutations cause genome-wide aberration of epigenetic modifica-
tions (Sasaki et al., 2012) and have been proposed to play a role as
disease drivers (Ding et al., 2012; Wakita et al., 2013). In CMML,
the DNMT3A-R882H mutation confers a growth advantage of
HSPCs. The transformational ability of this mutation operates
through different mechanisms, including forming a protein com-
plex with CDK1, resulting in enhanced cell cycle activity. Thus,
CDK1 inhibition may be another approach to consider testing in
CMML (Xu et al., 2014).
CDK Inhibitors Targeting CDK1
Among CDK inhibitors, highly potent and selective pharmaco-
logical compounds targeting CDK1 have been more difficult to
develop, probably because the crystal structure of CDK1 has not
been reported, while the detailed structures of CDK2, 4 and 6
have been resolved (Wang et al., 2011). Moreover, the functions
of CDK1/cyclin B1 in human cancer had not been properly elu-
cidated similar to CDK4/CDK6/cyclin D. Multi-CDK inhibitors
that target CDK1 are well-tolerated in cancer patients (Byrd et al.,
2007; Tibes et al., 2008). In this section we will discuss selected
pan CDK inhibitors that also target CDK1 and are used in clinical
trials in hematologic malignancies.
Flavopiridol
Flavopiridol (Alvocidib, Sanofi Aventis) is one of the first-
generation CDK inhibitors. It is a pan-CDK inhibitor that
inhibits CDK1, 2, 4, 6, 7, and 9 as well as GSK3β (Supplementary
Table 4). Flavopiridol inhibits the C-terminal domain kinase
activity of P-TEFb (CDK9/cyclin T) (IC50 3 nM) (Chao et al.,
2000) more potently than other CDKs including CDK7 (IC50
110–300 nM) (Sedlacek, 2001). Furthermore, inhibition of CDK9
by flavopiridol is non-competitive with respect to ATP (Chao
and Price, 2001). As a consequence of CDK9 inhibition, p-TEFb
is inactivated and most RNA transcription in vivo is blocked
that involves cell cycle and apoptosis regulators with short-lived
mRNAs (Chao and Price, 2001; Lam et al., 2001).
Preclinical studies demonstrated that flavopiridol induces cell
cycle arrest and apoptosis in hematopoietic cell lines of B-cell,
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T-cell and myeloid lineages (Parker et al., 1998). In preclinical
animal models of localized and disseminated human leukemia
and lymphoma, flavopiridol produces selective apoptosis of cells
in the thymus, spleen, and lymph nodes, resulting in atro-
phy of these organs and induces complete or major regression
of xenografts of human hematopoietic tumors (Arguello et al.,
1998).
Flavopiridol was the first CDKI inhibitor to enter clinical tri-
als in humans in the late 1990s (Senderowicz et al., 1998; Kel-
land, 2000). However, despite the promising preclinical findings,
results of early clinical trials using flavopiridol as single agent
employing either 72-h continuous or 1-h bolus infusion sched-
ules were disappointing (Byrd et al., 2005). The use of flavopiridol
in the clinic has also been hampered by complex pharmacokinet-
ics requiring prolonged intravenous administration, and toxici-
ties, including neutropenia, hypotension, and diarrhea (Dickson,
2014; Pitts et al., 2014).
Approximately 60 clinical trials using flavopiridol as a sin-
gle agent or in combination with conventional chemotherapeu-
tic drugs have been completed and/or are ongoing. Twenty six
of these trials are for hematologic malignancies, including CLL,
AML, ALL, CML, lymphocytic lymphoma, MCL, MM, and the
remaining trials are for solid tumors, including breast, prostate,
melanoma, pancreatic cancer, germ cell tumors, ovarian, lung,
and esophageal cancer (clinicaltrials.gov accessed 11/2014). Most
of these trials are completed or terminated. Only the cur-
rently active trials in hematologic malignancies are shown in
(Supplementary Table 4).
Flavopiridol as 30-min bolus dose followed by a 4-h infu-
sion produced sustained micromolar concentrations of flavopiri-
dol for several hours in a phase I trial in patients with
relapsed/refractory, genetically high-risk CLL; 45% PR was
observed (Byrd et al., 2007). Hematologic improvement has been
reported in a patient with hairy cell leukemia refractory to pen-
tostatin and rituximab (Jones et al., 2012). When flavopiridol is
given in a timed sequential fashion with cytarabine and mitox-
antrone (FLAM regimen), direct anti-leukemia cytotoxicity and
encouraging clinical responses are observed in patients with
poor-risk newly diagnosed and relapsed/refractory AML. FLT3-
mutant AMLs are particularly susceptible to the FLAM strategy
(Karp et al., 2003, 2005, 2007, 2010, 2012). A phase 1 trial in 55
adults with relapsed/refractory acute leukemias began at a total
flavopiridol dose of 50 mg/m2 per day 3 times (20 mg/m2 bolus,
30mg/m2 infusion). DLTs occurred at level 6 (30mg/m2 bolus,
70mg/m2 infusion) with tumor lysis, hyperbilirubinemia, and
mucositis. Death occurred in 5 patients (9%). CR occurred in 22
(40%) across all doses. Overall and disease-free survivals for CR
patients were more than 60% at more than 2 years (Karp et al.,
2011).
Dinaciclib
Dinaciclib (SCH 727965, Merck) is a pyrazolo [1,5-α]pyrimidine
that potently inhibits CDK1, CDK2, CDK5, and CDK9 (Parry
et al., 2010; Paruch et al., 2010) with IC50 values ranging from 1
to 4 nM in a broad spectrum of human cancer cell lines including
MCL, NHL, leukemia, colon, pancreatic, breast, prostate, SCLC,
liver, and bladder (Parry et al., 2010). In addition to its direct
interaction with the ATP-binding site, dinaciclib has also been
shown to interact with the acetyl-lysine recognition site of bro-
modomains (Martin et al., 2013). In the preclinical testing dinaci-
clib demonstrated superior efficacy and therapeutic index com-
pared to flavopiridol using the A2780 ovarian carcinoma murine
xenograft model (Parry et al., 2010). The efficacy here refers to
IC50 values and the minimal effective dose (MED) of both drugs
given by the same schedule, associated with >50% tumor growth
inhibition (Parry et al., 2010). Dinaciclib potently inhibits prolif-
eration and induces apoptosis in a number of adult cancer cell
lines and induces growth inhibition or regression in xenograft
models using a variety of administration schedules (Parry et al.,
2010). Preclinical evaluation of dinaciclib by the Pediatric Pre-
clinical Testing Program (PPTP) in a panel of 23 cell lines showed
a median IC50 of 7.5 nM (Gorlick et al., 2012). In an in vivo
panel of 43 xenograft models of common childhoodmalignancies
dinaciclib at a dose of 40mg/kg administered intraperitoneally
twice weekly for 2 weeks and repeated at day 21 with a total obser-
vation period of 6 weeks induced significant delays in event free
survival distribution compared to control in 64% of solid tumor
xenografts and in 43% of ALL xenografts (Gorlick et al., 2012). In
patient-derived CLL cell lines, dinaciclib promotes apoptosis and
abrogates microenvironment cytokine protection (Johnson et al.,
2012). Dinaciclib inhibits Mcl-1 expression and induces PARP
cleavage in peripheral blood mononuclear cells (PBMCs) from
patients with AML and ALL 4 h after infusion. Prolonged expo-
sures to dinaciclib, at clinically attainable concentrations, resulted
in enhanced leukemia cell death (Gojo et al., 2013).
There are currently 16 clinical trials testing dinaciclib (SCH
727965) as single agent or in combination with other agents in
patients with solid tumors (7 trials) and hematologic malignan-
cies (9 trials) (clinicaltrials.gov accessed 11/2014). Of the nine
trials for hematological malignancies, 2 trials have been termi-
nated for patients with MCL or B-Cell CLL (Study P04715) and
for those with AML or ALL (P04717AM2). Four studies are com-
pleted: Phase 1 Weekly Dosing of SCH 727965 in patients With
advanced cancer (Study P04629AM6), including NHL, MM, B-
cell CLL; Phase 1 Every-3-Week Dosing of SCH 727965 in
Patients With Advanced Cancer (Study P04630) including NHL
and MM; a third study in MM; and A Study of Dinaciclib in
Combination With Rituximab in Participants With CLL and SLL
(P07974). Three studies are currently active; one in MM, and two
studied in CLL and lymphoma (Supplementary Table 4).
In a phase II study in adult patients with relapsed/refractory
AML (n = 14) and ALL (n = 6) treated with dinaciclib at
50mg/m2 given as a 2-h infusion every 21 days, most patients
had dramatic but transient reduction in circulating blasts; how-
ever, no BM remissions were achieved on this schedule (Gojo
et al., 2013). The most common toxicities were gastrointestinal,
fatigue, transaminitis, and tumor lysis syndrome (TLS), includ-
ing one patient who died of acute renal failure (Gojo et al., 2013).
Based on the data that the expression of CDK5 is higher in MM
compared to normal organs, a phase I/II trial of dinaciclib as
a single agent was conducted in patients with relapsed MM at
doses of 30–50mg/m2, administered on day 1 of a 21-day cycle
(Kumar et al., 2015). The MTD was determined to be 50mg/m2
per day, the dose used in the Phase II portion (Bose et al., 2013).
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Overall, 27 evaluable patients were accrued; median number of
prior therapies was 4. The overall confirmed response rate (≥PR)
was 3 of 27 (11%); including one patient at 30-mg/m2 dose [1
very good response rate (VGPR)] and two patients at 40mg/m2
dose (1VGPR, 1 PR)] (Kumar et al., 2015). Leukopenia, throm-
bocytopenia, gastrointestinal symptoms, alopecia, and fatigue,
were the most common adverse events. Because CDK5 inhibition
can enhance the activity of proteasome inhibitors in vitro, ongo-
ing studies are investigating the combination of dinaciclib with
proteasome inhibitors (Kumar et al., 2015).
In a phase I study of dinaciclib in combination with rituximab
in patients with relapsed/refractory CLL, only five patients com-
pleted the study due to early termination of the enrollment in the
study and all presented with drug-related adverse events (AEs),
but no DLTs were observed. The most commonly observed toxi-
cities included hematological with a frequency of≥40%, digestive
and metabolic. Four patients achieved stable disease, and one
patient achieved a CR. PK samples showed no obvious interaction
between dinaciclib and rituximab (Fabre et al., 2014).
AT7519
The pyrazole-3-carboxamide AT7519 (ASTEX) is another pan-
CDK inhibitor that is highly active against CDK9 (IC50 <10 nM)
and CDK5 (IC50 = 13 nM) followed by CDK2 (IC50 = 47 nM).
It inhibits CDK1/cyclin B with an IC50 = 210 nM) (Squires et al.,
2009) (Supplementary Table 4). Because of its high affinity toward
CDK9, the mechanism of AT7519 is mainly through inhibition of
transcription. Indeed, AT7519 inhibited RNApol II phosphoryla-
tion, a CDK9 substrate, associated with decreased RNA synthesis
in MM cell lines (Santo et al., 2010). Preclinical testing of AT7519
showed that it has antiproliferative activity and induces apoptosis
in MM cell lines and MM tumor model through GSK3β acti-
vation and RNA pol II inhibition (Santo et al., 2010). AT7519
induces apoptosis at concentrations of 100 to 700 nM in leukemia
cell lines and samples from patients with CLL with inhibition of
phosphorylation of the RNA pol II, downregulation ofMcl-1, and
PARP cleavage (Squires et al., 2010).
Currently there are four clinical trials with AT7519 as sin-
gle agent or in combination with other agents (clinicaltrials.gov
accessed 11/2014). Three are active trials: Phase I/II study in com-
bination with bortezomib in MM, a Phase II study in MCL and
a Phase II in CLL (Supplementary Table 4). One Phase I study
has been completed in advanced or metastatic solid tumors or
refractory NHL. AT7519 was given as a 1-h intravenous infusion
on days 1, 4, 8, and 11 every 3 weeks. DLTs included mucositis,
febrile neutropenia, rash, fatigue and hypokalemia. The recom-
mended phase II dose (RP2D) was 27.0mg/m2 per day. Ten of 19
patients had stable disease as the best response (median duration:
3.3 months; range: 2.5–11.1 months) (Chen et al., 2014).
P276-00
P276-00 (Nicholas Piramal, India), a flavone derivative, is an ATP
competitive small molecule inhibitor of CDK9 (IC50 = 63 nM),
CDK4 (IC50 = 79 nM) and CDK1 (IC50 = 224 nM). P276-00
shows potent antiproliferative effects against various human can-
cer cell lines including the AML cell line (HL-60) and is highly
selective for cancer cells as compared with normal fibroblast cells
(Joshi et al., 2007). P276-00 decreases cellular levels of cyclin D1,
an effect that can be attributed to inhibition of CDK9 transcrip-
tional activity. It inhibits CDK4/cyclin D1 activity, downregulates
pRb Ser780 phosphorylation, and induces apoptosis by the induc-
tion of caspase-3 (Joshi et al., 2007). P276-00 also downregulates
Mcl-1 and induces PARP cleavage in MM cell lines (Raje et al.,
2009) through inhibition of CDK9-T1 and RNA pol II-dependent
transcription (Manohar et al., 2011) and shows antitumor activity
in a MM xenograft model. Combination with bortezomib results
in synergism (Raje et al., 2009). Similar results were obtained in
MCL in vitro and in vivo (Shirsath et al., 2012). Synergistic effects
with doxorubicin at suboptimal doses in NSCLC cell lines are also
reported (Rathos et al., 2013).
There are seven completed and three terminated Phase I
or Phase II studies. One trial is in MM, another Phase II
study includes patients with MCL and the remaining stud-
ies are in solid tumors (clinicaltrials.gov, accessed 11/2014)
(Supplementary Table 4).
TG02
TG02 (Tragara Pharmaceuticals) is a pyrimidine-based pan-
CDK/FLT3/JAK2 inhibitor that inhibits CDKs 1, 2, 7, and 9
together with JAK2, FLT3 (William et al., 2012), and ERK5
(Alvarez-Fernandez et al., 2013; Ortiz-Ruiz et al., 2014) with IC50
of 13, 73, and 56 nM for CDK2, JAK2, and FLT3, respectively
(William et al., 2012). TG02 is anti-proliferative in a broad range
of tumor cell lines, in primary cultures of progenitor cells derived
from AML and from patients with polycythemia vera, inducing
G1 cell cycle arrest and apoptosis. In vivo, TG02 induces tumor
regression after oral dosing on both daily and intermittent sched-
ules in a murine model of FLT3-ITD leukemia (MV4-11) and
prolongs survival in a disseminated AML model with wt FLT3
and JAK2 expressed in HL-60 AML cell lines (Goh et al., 2012).
TG02 at 100 nM is potently cytotoxic toward CD34(+) CD38(−)
CD123(+) positive and unfractionated AML cells from patients.
The antitumor activity of TG02 is likely mediated by dephos-
phorylation of RNA Poly II leading to transcription repression
of survival molecules such as Mcl-1 and XIAP, with subsequent
BAX activation and apoptosis (Pallis et al., 2012; Ortiz-Ruiz et al.,
2014). TG02 induced similar effects in MM cell lines, displayed
significant activity in two MM xenograft models, and enhanced
the in vivo activity of bortezomib and lenalidomide (Alvarez-
Fernandez et al., 2013; Ortiz-Ruiz et al., 2014) in a xenograft
model of triple negative breast cancer (Ortiz-Ruiz et al., 2014).
Currently there are two active Phase I clinical trials of TG02
in CLL, small lymphocytic lymphoma and in advanced hemato-
logic malignancies. The latter consists of three arms (1) TG02 as
single agent in patients with acute leukemia, (2) as single agent in
patients with MM and (3) TG02 in combination with carfilzomib
in patients with MM (Supplementary Table 4) (clinical trials.gov
accessed 11/2014).
RGB-286638
RBG-286638 (Agennix) is a novel indenopyrazole-derivative,
multi-kinase inhibitor. It potently inhibits CDKs 1, 2, 3, 4, 5,
6, 7, 9 as well as non-CDK kinases such as Jak1, Jak2, c-Src,
AMPK, and GSK3β (Supplementary Table 4) (Cirstea et al.,
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2013). RGB-286638 is cytotoxic in vitro in MM cell lines with
either wild type or mutant p53 and inhibits MM tumor growth
and prolongs survival in vivo. It induces caspase-dependent
apoptosis regardless of p53 status. It acts via down regulation
of RNA pol II phosphorylation and inhibition of transcription.
RGB-286638 also down regulates the oncogenic miR-19, miR-
92a-1, and miR-21 (Cirstea et al., 2013). So far only one Phase
I study of RGB-286638 in patients with solid tumors has been
conducted. RGB-286638 was given intravenously on days 1–5
every 28 days. Twenty-six patients were enrolled at 6-dose levels
from 10 to 160mg/d. Four DLTs were observed in two of the six
patients enrolled at the highest dose level. These toxicities were
AST/ALT elevations in one patient, paroxysmal supraventricular
tachycardias (SVTs), hypotension, and an increase in troponin
T. The recommended MTD for phase II studies is 120mg/d. Pro-
longed disease stabilization (range, 2–14months) was seen across
different dose levels (Van Der Biessen et al., 2014).
Teramperprocol
Terameprocol (formerly known as EM-1421 and M4N) (Eri-
mos Pharmaceuticals) is a semisynthetic derivative of a naturally
occurring plant lignan. It selectively inhibits specificity protein
1 (Sp1)-regulated proteins, including CDK1, survivin and VEGF
(Castro-Gamero et al., 2013), thus inhibiting the cell cycle, trig-
gering apoptosis and decreasing angiogenesis. Preclinical studies
have demonstrated the potent anticancer activity of terameprocol
in tumor cell lines and animal models (Smolewski, 2008).
There have been 6 clinical trials with terameprocol (EM-1421)
(clinicaltrials.gov, accessed 11/2014). In a phase I clinical trial
including 25 patients with solid tumors, 8 patients exhibited sta-
ble disease and 17 had progressive disease; the drug was generally
well-tolerated (Smolewski, 2008). Other phase I/II clinical trials
have been for the treatment of glioma, treatment-refractory solid
tumors, and cervical dysplasia. A Phase I study in patients with
advanced leukemias was conducted with 16 patients treated with
1000, 1500, or 2200mg of intravenous terameprocol 3×/week for
2 of 3 weeks. No DLT was observed, and the RP2D was deter-
mined to be 1500mg 3×/week for 2 of 3 weeks cycle. Five AML
patients had stable disease greater/equal to 2 months (Tibes et al.,
2014).
WEE-1 Kinase
WEE-1 is a protein kinase that plays a central role in the proper
timing of cell division cycle by modulating the activities of CDK1
and CDK2 through inhibitory phosphorylation of conserved
Tyr15 residues on both kinases, thereby controlling entry into
mitosis and DNA replication during S phase (Do et al., 2013).
WEE-1 plays a critical role in maintaining genome integrity and
is essential for embryonic survival at the pre-implantation stage
of mouse development (Tominaga et al., 2006). Mice deficient for
WEE-1 die before E3.5. Wee1−/− embryos are defective in the
G2/M cell cycle checkpoint induced by γ-irradiation resulting in
widespread apoptosis. Acute ablation of WEE-1 in MEFs results
in growth defects and cell death, aneuploidy, DNA damage, and
CHK2 activation (Tominaga et al., 2006).
In the mammalian cell cycle there are three checkpoints
that function in G1, S and G2, respectively. Depending on
the type of genotoxic stress, either ataxia-telangiectasia mutated
(ATM) protein kinase (Supplementary Table 2, Figure 2) or
ataxia-telangiectasia-related (ATR) protein kinase is preferen-
tially activated (Do et al., 2013). ATM is activated in response to
ionizing radiation, radiomimetic agents, and agents, which cause
double-strand DNA breaks (DSBs). It phosphorylates and acti-
vates CHK2, which, in turn, phosphorylates CDC25C at Ser216,
creating a binding site for the 14-3-3σ protein (Matsuoka et al.,
2000). This leads to nuclear export and cytoplasmic sequestration
of CDC25C. Suppression of CDC25C phosphatase activity results
in inhibitory phosphorylation of the CDK1/cyclin B complex,
maintaining CDK1 in an inactive form and preventing entry into
mitosis (Figure 2). If the checkpoints are defective (or pharma-
cologically inhibited) DNA damage will not be repaired and cells
die due to accumulation of genetic lesions. ATR is activated by
a broader range of genotoxic stimuli that result in single-strand
DNA breaks (Jazayeri et al., 2006; Johnson et al., 2009). ATR
phosphorylates and activates CHK1 that can also be activated by
ATM. CHK1 then phosphorylates WEE-1 and CDC25C, thereby
activatingWEE-1 kinase activity and inactivating CDC25C phos-
phatase activity. WEE-1, then, phosphorylates and inactivates
CDK1/cyclin B complex on Tyr15 residue, resulting in cell cycle
arrest at G2, allowing time for DNA repair (Do et al., 2013).
The concept of using WEE-1 inhibitors in cancer therapy is
based on the notion that by abrogating the G2 checkpoint, in the
presence of DNA damaging agents such as cytarabine, used in
the treatment of AML, cells would die in mitosis (mitotic catas-
trophe). This would be of particular relevance in cells in which
p53 is deleted or mutated, as is the case in many human cancer
types. The G1 checkpoint is controlled by p53 (Figure 2). If p53 is
defective, genetic lesions will accumulate and cells will depend on
the G2 checkpoint for repair, but if the G2 checkpoint is also non-
functional, therefore, unrepaired DNA will further accumulate
leading to mitotic catastrophe and/or death by apoptosis. Indeed,
the combination of DNA-damaging cancer therapy with WEE-
1 inhibition catalyzes mitotic catastrophe (De Witt Hamer et al.,
2011). The WEE-1 inhibitor PD0166285 abrogates G2/M check-
point inducing early cell division in the B16 melanoma cell line
and this effect is related to microtubule stabilization and decrease
in cyclin D transcription (Hashimoto et al., 2006). Using a micro-
tubule interfering compound we observed a similar phenotype
of accumulation of cells in mitosis with high CDK1 activity that
leads to mitotic catastrophe and apoptosis (Waraky et al., 2014).
Checkpoint kinases (CHK1 and CHK2) are also considered
therapeutic targets in cancer including hematologic malignan-
cies. The therapeutic targeting of checkpoint kinases and mitotic
kinases (Polo-like kinases and Aurora kinases) were previously
discussed in details in recent reviews (Lapenna and Giordano,
2009; Moore et al., 2013; Gojo and Karp, 2014; Pitts et al., 2014).
WEE-1 in Human Cancer
WEE-1 is overexpressed in several cancers including primary
AML, ALL, and CML specimens (Tibes et al., 2012). High
expression of WEE-1 in malignant melanoma correlates with
poor disease-free survival (Magnussen et al., 2012). Recently, an
INDELwas identified in the poly-T track of the 56 bp non-coding
region of WEE-1 in pancreatic adenocarcinoma, which contains
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FIGURE 2 | DNA damage pathways and how CHK1-, WEE1-, or CDK1
inhibitors can synergize with cytarabine to increase its DNA
damaging efficacy in AML. Ataxia-telangectasia mutated (ATM) protein
kinase is activated in response to ionizing radiation (IR), radiomimetic agents,
and agents which cause double-strand DNA breaks (DSBs).
Ataxia-telangiectasia-related (ATR) protein kinase is activated by a broader
range of genotoxic stimuli that result in single-strand DNA breaks (SSB). In
addition, ATM can also activate ATR. Initial sensing of DNA damage can also
be mediated by the NBS1-MRE11-RAD50 complex and by
RAD17-RAD1-HUS1-RAD9 at the site of DNA breaks. This is followed by
phosphorylating CHK2, p53, MDM2 and CHK1, which mediate cell cycle
checkpoint responses to arrest the cells until DNA damage is repaired.
Activated p53 will induce p21 and the CDC25A protein, which inhibit CDK2
and prevents G1/S transition. Altered phosphorylation (by CHK1) or
cytoplasmic sequestration of CDC25C (by 14-3-3σ) will inactivate
CDK1/cyclin B preventing cells from entering mitosis. CHK1 also
phosphorylates/activates WEE-1, which phosphorylates and inactivates
CDK1/cyclin B complex on Tyr15 residue, resulting in cell cycle arrest at G2,
allowing time for DNA repair. In AML, treatment with cytarabine (Ara-C)
activates the DNA damage pathway through CHK1, which stabilizes stalled
replication fork and induces S phase arrest. This will allow DNA damage
induced by Ara-C to be repaired. To increase the DNA damaging efficacy of
Ara-C the checkpoint pathway can be blocked by a selective CHK1 inhibitor
such as MK-8776 that overrides the S-phase checkpoint activation. To
overcome the G2/M checkpoint blocking WEE-1 kinase using the selective
inhibitor MK-1775 will result in CDK1 activation and cells die due to
accumulation of genetic lesions. CHEM, genotoxic chemicals; Rep stress,
replication stress; UV, ultra violet radiation.
the binding site of an RNA binding protein, HuR (important for
cancer cell survival). The incidence of a TT insertion is increased
in familial pancreatic cancer and results in decreased WEE-1
expression upon DNA damage (Lal et al., 2014). This INDEL can
have clinical implications in predicting chemo-responsiveness.
WEE-1 was also identified as a therapeutic target in AML (Porter
et al., 2012a), in medulloblastoma (Harris et al., 2014)and in
head and neck cancer (Wu et al., 2011). Inhibition of WEE-1
either by PD0166285 or by siRNA knockdown sensitizes solid
tumor cell lines to DNA damage by irradiation and topoiso-
merase inhibition (Wang et al., 2001, 2004; Posthumadeboer
et al., 2011).
Pharmacological Inhibitor of WEE-1 Kinase
MK-1775
MK-1775 (AZD1775, Merck), a recently developed pyrazolo-
pyrimidine derivative is a potent and selective ATP-competitive
small-molecule inhibitor of WEE-1 kinase with an IC50 value of
5.2 nM in in vitro kinase assays.
The WEE-1 inhibitor MK-1775 shares common mechanisms
of cell death with CHK1 inhibitors and combined WEE-1 and
CHK1 inhibition forcesmitotic entry from S-phase in the absence
of chemotherapy (also achieved by WEE-1 inhibition alone).
p53/p21 inactivation combined with high expression of mitotic
cyclins and EZH2 predispose cells tomitotic entry during S-phase
(Aarts et al., 2012). Combined treatment of a CHK1 inhibitor
(PF-00477736) and MK-1775 confirmed the marked synergis-
tic effect in various human cancer cell lines (breast, ovarian,
colon, prostate), independently of the p53 status. Cancer cells
undergo premature mitosis before the end of DNA replication,
with damaged DNA leading to cell death partly by apopto-
sis. These effects translated into increased tumor growth inhi-
bition in a xenograft model of ovarian cancer than with each
inhibitor as single agent and with no toxicity (Carrassa et al.,
2012).
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Combination of MK-1775 with Other Agents
Enhances Therapeutic Effects in Preclinical
Models of Leukemia
WEE-1 was identified as a therapeutic target for mutant RAS-
driven AML cell lines and primary patient samples using a
chemical screen to identify compounds capable of potentiat-
ing mammalian target of rapamycin (mTOR) inhibition. The
observed synergy enhances dephosphorylation of AKT, 4E-
binding protein 1 and s6 kinase, and correlates with increased
apoptosis. These findings suggest a combined WEE-1 /mTOR
inhibition as a novel therapeutic strategy for the selective treat-
ment of mutant RAS-positive leukemia (Weisberg et al., 2015).
Using RNAi screening of the kinome with cytarabine and a
genome-wide shRNA screen, WEE-1 was also identified as a
therapeutic target in myeloid leukemia (Tibes et al., 2012)
and a critical mediator of AML cell survival after cytarabine
exposure (Porter et al., 2012a). Pharmacologic inhibition of
WEE-1 is synergistic with cytarabine (Figure 2), increases apop-
tosis more than either drug alone, and prevents S-phase arrest
induced by cytarabine in AML cell lines and primary cells
(Porter et al., 2012a), as well as in ALL and CML cell lines
(Tibes et al., 2012). Similar observations have been reported
in pediatric Down Syndrome AML (DS-AML) cell lines CMK
and CMY, as well as primary DS-AML patient samples (Cald-
well et al., 2014). Adding MK1775 to cytarabine substan-
tially reduced viability in 13 of 14 AML, CML, and MDS
patient samples compared with cytarabine alone (Caldwell et al.,
2014).
Furthermore, MK-1775 produces synergistic inhibition in
combination with histone deacetylase inhibitors (HDACIs, for
example, vorinostat), which interrupt the DNA damage response,
to kill p53- wt or—mutant leukemia (Zhou et al., 2014). In addi-
tion, a similar effect has been observed in FLT3-ITD leukemia
cells in association with pronounced WEE-1 inhibition and
diminished CDK1 Tyr15 phosphorylation (Zhou et al., 2014).
The combination is active against patient-derived AML cells har-
boring either wt or mutant p53. CD34+/CD123+/CD38- pop-
ulations enriched for leukemia-initiating progenitors, but not
CD34+ normal hematopoietic progenitors, are highly susceptible
to this regimen. The combination of MK-1775 with vorinostat in
AML murine xenografts significantly reduces tumor burden and
prolongs animal survival (Zhou et al., 2014). Therefore, in AML,
mutant p53 is not a predictive biomarker for response to WEE-1
inhibition. This result was also confirmed in another preclinical
study after combination of cytarabine andMK-1775 for the treat-
ment of AML cell lines and AMLmousemodel (Van Linden et al.,
2013). Pre-treatment of the human leukemic T-cell lines, Jurkat
and MOLT-4, with the WEE-1 inhibitor 681641 or the Rad51
inhibitor RI-1 increases the sensitivity of Jurkat cells to irradi-
ation. However, combining both inhibitors together results in a
further enhancement of apoptosis (Havelek et al., 2014).
Similar to solid tumors, AML cell lines and patients’ blast
samples are sensitive to MK-1775 and to the combined effect
of MK-1775 and a CHK1 inhibitor. Patient samples harbor-
ing t(15;17) translocation are significantly more sensitive to
MK-1775 than non-t(15;17). CHK1 induction by MK-1775 is
suggested as a potential mechanism of resistance to MK-1775
treatment. MK-1775 induces DNA damage, which activates
CHK1. CHK1 phosphorylates CDC25, inhibiting the dephos-
phorylation of CDK1/2, thus countering the effects of MK-1775.
Therefore, activation of CHK1 can be overcome by the addi-
tion of a CHK1 inhibitor, resulting in a synergistic, anti-leukemic
activity (Qi et al., 2014).
There are 20 clinical studies with MK-1775 in solid tumors in
Phase I and II stages, but no trials in hematological malignancies
yet (Supplementary Table 4) (clinicaltrials.gov, accessed 11/2014).
Cyclin C-CDK3/CDK8/CDK19
Cyclin C associates with CDK3 to phosphorylate pRB, thus pro-
moting cell cycle entry from quiescence (Ren and Rollins, 2004).
Indeed, knockdown of cyclin C increases quiescence in HSPC
(Miyata et al., 2010). Cyclin C also associates with CDK8 (Leclerc
et al., 1996) and with CDK8-related CDK19 (Tassan et al., 1995;
Li et al., 2014). This complex has a major role in transcription. It
is a component of RNA pol II transcription initiation complexes
and represses transcription by phosphorylating the CTD of the
largest RNA pol II subunit (Liao et al., 1995; Tassan et al., 1995;
Leclerc et al., 1996; Rickert et al., 1996), as well as by inhibit-
ing the general transcription factor TFIIH (Akoulitchev et al.,
2000). Cyclin C/CDK8 is also incorporated into the inhibitory
module of the transcriptional mediator complex, and blocks the
interaction of the mediator complex with RNA pol II (Elmlund
et al., 2006; Knuesel et al., 2009). In fact, cyclin C/CDK8 plays
a dual role in regulating transcription; as a negative regulator
through phosphorylation and suppression of transcription fac-
tors (Chi et al., 2001; Nelson et al., 2003; Fryer et al., 2004; Alarcon
et al., 2009), or by activating transcription either as a part of the
basal transcriptional machinery, or downstream of p53, and of
theWnt/β-catenin pathway (Donner et al., 2007, 2010; Furumoto
et al., 2007; Firestein et al., 2008; Morris et al., 2008).
Mouse Models Reveal a Critical Role for Cyclin C
as a Tumor Suppressor in T-ALL
Genetic ablation of cyclin C in the mouse results in embryonic
lethality at E10.5 (Li et al., 2014). Cyclin C plays a major role in
hematopoiesis. Ablation of cyclin C in the hematopoietic system
in vivo results in enlargement of the thymus and stabilization of
the intracellular Notch1 (ICN1) proteins (Li et al., 2014). Indeed,
ICN1 is phosphorylated by cyclin C/CDK8 complexes result-
ing in increased ubiquitination by the SCF (Skip1–Cullin1–F-
box)–Fbw7 ubiquitin ligase that leads to proteasome-dependent
degradation (Fryer et al., 2004; Thompson et al., 2007). Acti-
vation of Notch1 is triggered by a ligand-dependent prote-
olytic cleavage that results in the release of the ICN1 protein,
which translocates to the nucleus, thereby inducing target-gene
transcription (Gordon et al., 2008; Trakala and Malumbres,
2014). Notch1 is a potent T-cell oncogene, with >50% of T-
ALL cases carry activating mutations in the Notch1 receptor,
many of which truncate the Notch1 C-terminal domain con-
taining the PEST domain, resulting in increased ICN1 stability.
Cyclin C/CDK3/CDK8/CDK19 complexes phosphorylate ICN1
on residues T2512, S2514, and S2517 located in the PEST-domain
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leading to its degradation (Li et al., 2014). Therefore, cyclin
C/CDK3/CDK8/CDK19 complexes function as tumor suppres-
sors in T-ALL by preventing the accumulation of ICN1 and the
lack of these complexes led to enhanced T-ALL development in
Lck-LMO1 transgenic mice that mimic the alterations found in
human T-ALL (Li et al., 2014). It is noteworthy to mention that
Notch appears to have different effects in hematologic malignan-
cies. While Notch signaling inhibits AML growth and survival,
thus functioning as a tumor suppressor in AML (Kannan et al.,
2013), in other studies Notch signaling had variable effects on
AML growth and survival, depending on the individual AML
sample (Tohda et al., 2005).
Cyclin C/CDK8-CDK19 in Human Cancer
In human, CCNC and CDK19 genes lie very close to each other
on the 6q21 region of the human chromosome 6, a region that
is frequently deleted in multiple malignancies including breast,
lung, ovarian, prostate carcinomas, leukemia and osteosarcoma
(Trakala and Malumbres, 2014). Co-deletion of CCNC and
CDK19 takes place in 10% of T-ALL (Li et al., 2014) or 7% of
DLBCL (Trakala and Malumbres, 2014). In addition, five muta-
tions (out of 73 T-ALL patients) were identified in the cyclin-
C/CDK recognition sites in the Cdc4 phosphodegron of Notch1
leading to ICN1 stabilization and were able to enhance T-ALL
development when reproduced in mouse models, supporting the
notion that alteration of the cyclin-C/CDK-dependent regulation
of Notch1 contributes to human leukemia (Li et al., 2014). While
CDK19 is downregulated in leukemia, lymphoma and esophageal
cancer, CDK8 is overexpressed and amplified in ∼50% of colon
cancers suggesting a selective role of CDK8 in this type of tumors
(Firestein et al., 2008; Morris et al., 2008). CDK8 phosphorylates
and inhibits E2F1, an inhibitor of β-catenin function, resulting in
increased activity of the Wnt/β-catenin pathway in colon cancer
cells (Morris et al., 2008) and suppression of CDK8 expression
in these cells inhibits proliferation (Firestein et al., 2008). CDK8
and cyclin C expression also correlate with poor survival in breast
cancer and with platinum treatment failure in ovarian cancer
(Porter et al., 2012b). Therefore, because of the dual role of the
cyclin C/CDK8/CDK19 complexes functioning in some tumors
as oncogenes and in other tumors as tumor suppressor genes
the use of pharmacological inhibitors of this complex should be
carefully considered depending on tissue type.
Pharmacological Inhibitor of CDK8
Senexin A was reported to bind CDK8 at the ATP pocket and
to inhibit its cellular functions (IC50 = 280 nM) including the
potentiation of β-catenin–dependent transcription. It also binds
to CDK19 in an ATP-competitive manner (Porter et al., 2012b).
In these studies p21 was found to bind to CDK8 and stimu-
late its kinase activity and was required for disease-promoting
paracrine activities associated with DNA damage and senescence
induced by chemotherapy. Senexin A also increases the efficacy of
chemotherapy against xenografts formed by tumor cell/fibroblast
mixtures (Porter et al., 2012b). It inhibits p21-induced tran-
scription and reverses doxorubicin-induced tumor-promoting
paracrine activities in vivo (Porter et al., 2012b).
Due to their potential ability to stabilize Notch, cyclin
C/CDK8/19 inhibitors may be of therapeutic benefit for the
hematologic malignancies in which Notch functions as a tumor
suppressor such as CML (Yin et al., 2009; Yang et al., 2013b) and
CMML (Klinakis et al., 2011).
Concluding Remarks
The main function of cell cycle protein kinases, including CDKs,
was initially identified as drivers of cell cycle progression. In part
because dysregulation of this process is one of the hallmarks
of cancer, several first generation pharmacological inhibitors
targeting CDKs have been developed. Most of these are ATP
competitive inhibitors. However, major drawbacks of these pan
CDK inhibitors include lack of selectivity toward tumor cells,
off-target effects, which increase their toxicity, and unfavorable
pharmacokinetics. In contrast, specific CDK inhibitors should
provide selectivity and reduced toxicity because tumor cells
may be selectively dependent on a certain pathway such as the
cyclin D/CDK4/6/Rb pathway. The further development of spe-
cific CDK inhibitors may lead to significant advances in cancer
treatment.
Experiments using mouse models deficient for CDKs have
revealed that they also regulate differentiation, stem cell renewal,
DNA repair, angiogenesis, and transcription with selective tissue
dependence. Some CDKs act as oncogenes, while others function
as tumor suppressors; they are altered in cancer by functionally
relevant mutations and/or by altered expression and activities.
Such information has led to a renewed interest in these pathways
as therapeutic targets. For example, the CDK4/6 inhibitor, palbo-
ciclib, is emerging as a potentially useful agent after more than
a decade in drug development limbo. Palbociclib and the related
LEE011, as well as dinaciclib, are currently in Phase III clinical tri-
als. Palbociclib has demonstrated promising single-agent activity
in MCL.
Most of the pan-CDK inhibitors induce cell cycle arrest, apop-
tosis and/or transcriptional repression. Improved anti-tumor
responses are usually observed when this class of molecularly
targeted agents is used in combination with traditional cyto-
toxic drugs, such as flavopiridol and cytarabine for AML. Alter-
natively, combination with other targeted compounds, such as
proteasome inhibitors (bortezomib) in MM or NHL has shown
promising enhancement of anti-tumor responses. The disruption
of DNA repair pathways using CHK1 inhibitors has shown syn-
ergy with cytarabine in preclinical studies of AML. Similar results
have been observed with combinations of cytarabine and WEE-1
inhibitors. Another identified complex that plays a critical role in
the development of Notch-dependent T-ALL is the cyclin C with
its associated kinases CDK3/8/19. Further studies of this path-
way in different types of human cancer and the development of
compounds targeting these complexes are needed.
An unexplored yet important area that also needs to be
addressed is the efficacy of cell cycle inhibitors in pediatric malig-
nancies. Pediatric AML, for example, remains a challenging dis-
ease with overall survival between 50 and 60%. Conventional
AML therapy is basically the same for adults and children, based
on cytarabine and anthracycline combinations. Relapsed AML
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refractory to chemotherapy has an overall survival less than 20%.
Cell cycle inhibitors are currently in clinical trials as targeted
agents in pediatric AML or ALL; the Aurora A inhibitor alisertib
in a phase II trial and the Aurora A/B inhibitor AT9283 is in phase
I (Napper and Watson, 2013). The WEE-1 kinase inhibitor MK-
1775 in combination with cytarabine may be another promis-
ing new treatment approach for Down Syndrome-AML that will
need clinical testing.
A key question regarding the clinical development of cell
cycle inhibitors in pediatric AML is the identification of the
molecular signatures that predict susceptibility to these com-
pounds. One approach is currently being tested, as part of a
national St. Baldrick Foundation (SBF) Pediatric AML Consor-
tium (SBF-PAC). This consortium is focused on the clinically
real time identification of altered key leukemia pathways along
with the integration of functional assays, such as kinase inhibition
screens, single cell network profiling and drug inhibition screens,
to define and validate driver pathways. This information is linked
to a clinical trial designed to test molecularly directed therapies
in pediatric AML. Some of the pathways identified define pivotal
genes regulating leukemia survival, cell proliferation and path-
ways driving leukemia resistance to conventional therapies. In
this context, further exploration of inhibitors targeting cell cycle
kinases in pediatric AML is warranted.
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